About this Research Topic
Please note that this Research Topic is reserved for invited submissions. If you were not contacted by the Topic Editors to contribute, please submit to another Research Topic or to the relevant specialty section.
Because of the advance in high-throughput molecular profiling of cancer cells, our understanding of the molecular events governing thyroid carcinogenesis has helped the development of the more accurate risk-stratification; the personalized diagnostic; and therapeutic strategies for patients with thyroid cancer. The insight in molecular alterations identified in thyroid cancer has gradually been incorporated into all aspects of thyroid cancer management. These aspects include diagnosis, prognostic, and treatments by tailoring the management to specific tumor biology. The integration of comprehensive analyses of multi-omic alterations, such as genomics, transcriptomics, epigenomics, metabolomics, and proteomics, can lead to the improved outcome of patients with thyroid cancer.
The crucial areas in the management of patients with thyroid cancers currently includes the risk-stratification to identify high-risk patients and the novel systemic treatments in iodine-resistant and aggressive thyroid cancers. The goal of this collection is to comprehensively review the role of multi-omics, the metabolic reprogramming, tumor microenvironment, tumor-related immunology in thyroid cancer carcinogenesis, progression, and treatment resistance. The clinical relevance and the potential translation to clinical uses of the molecular alterations are discussed.
Articles in this research topic will include basic, translational, and clinical findings to give an overview of the latest discoveries using innovative approaches in molecular thyroid carcinogenesis and applied to targeted therapies and precision medicine for patients with thyroid cancer. This research topic invites, but is not limited to, the following research aspects:
-Multi-omics signature in thyroid cancer;
-Metabolic reprograming in thyroid carcinogenesis;
-Tumor micro-environment in thyroid cancer;
-Thyroid cancer immunology;
-Prognostic markers;
-Targeted therapies.
Because of the advance in high-throughput molecular profiling of cancer cells, our understanding of the molecular events governing thyroid carcinogenesis has helped the development of the more accurate risk-stratification; the personalized diagnostic; and therapeutic strategies for patients with thyroid cancer. The insight in molecular alterations identified in thyroid cancer has gradually been incorporated into all aspects of thyroid cancer management. These aspects include diagnosis, prognostic, and treatments by tailoring the management to specific tumor biology. The integration of comprehensive analyses of multi-omic alterations, such as genomics, transcriptomics, epigenomics, metabolomics, and proteomics, can lead to the improved outcome of patients with thyroid cancer.
The crucial areas in the management of patients with thyroid cancers currently includes the risk-stratification to identify high-risk patients and the novel systemic treatments in iodine-resistant and aggressive thyroid cancers. The goal of this collection is to comprehensively review the role of multi-omics, the metabolic reprogramming, tumor microenvironment, tumor-related immunology in thyroid cancer carcinogenesis, progression, and treatment resistance. The clinical relevance and the potential translation to clinical uses of the molecular alterations are discussed.
Articles in this research topic will include basic, translational, and clinical findings to give an overview of the latest discoveries using innovative approaches in molecular thyroid carcinogenesis and applied to targeted therapies and precision medicine for patients with thyroid cancer. This research topic invites, but is not limited to, the following research aspects:
-Multi-omics signature in thyroid cancer;
-Metabolic reprograming in thyroid carcinogenesis;
-Tumor micro-environment in thyroid cancer;
-Thyroid cancer immunology;
-Prognostic markers;
-Targeted therapies.
Keywords: Thyroid cancer, multi-omics, biomarkers, precision medicine, targeted therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
